SB 273005

Drug Profile

SB 273005

Latest Information Update: 05 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Osteoporosis therapies
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 05 Nov 2002 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
  • 18 Apr 2002 Discontinued - Phase-I for Postmenopausal osteoporosis in USA (unspecified route)
  • 20 Mar 2001 Phase-I clinical trials for Postmenopausal osteoporosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top